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Breast cancer cella b s t r a c t
The p75 neurotrophin receptor (p75NTR) undergoes sequential proteolytic cleavages leading to the
generation of a carboxyl-terminal fragment (p75NTR-CTF) and an intracellular domain (p75NTR-
ICD) in many cellular models. We have previously shown that p75NTR is involved in the survival of
breast cancer cells. Here, we demonstrated that p75NTR cleavage occurs also in these cells. Surpris-
ingly, p75NTR-CTF increased cell survival, whereas p75NTR-ICD had no effect. The pro-survival effect
of p75NTR-CTF was associated with a decrease of TNF-related apoptosis-inducing ligand (TRAIL)-
induced PARP and caspase 3 cleavages. Finally, our ﬁndings indicate that p75NTR could favor cell sur-
vival via its carboxyl-terminal fragment, independently of PI3-kinase, NF-jB, or MAP kinase signal-
ing pathways.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
p75 Neurotrophin receptor (p75NTR) is the common receptor for
all the neurotrophins (NGF, BDNF, NT-3 and NT-4) and their pre-
cursors. It is a member of the TNF receptor superfamily that in-
cludes the Fas (CD95) antigen, CD30, and CD40. This family of
receptors is distinguished with multiple cysteine-rich domains
for ligand binding, a single transmembrane sequence, and a non-
catalytic cytoplasmic domain containing a death domain sequence
[1]. Since its identiﬁcation and cloning in the 1980s, p75NTR has
been reported to be involved in diverse and often contradictory
functions such as survival, apoptosis, neurite outgrowth, differen-
tiation, proliferation and migration, depending on the cell type
and cellular context [1,2]. In some cases, p75NTR is an inducer of
apoptosis, even without NGF stimulation [3], whereas in other
cases the activation of p75NTR by NGF results in a protection fromcell death [4]. p75NTR, through a neurotrophin-dependent mecha-
nism, dramatically enhances migration and invasion of melanoma
and glioma cells [5,6]. We have shown that p75NTR favors survival
of breast cancer cells [7–9].
p75NTR exerts its diverse effects through several signaling path-
ways including Ras homolog gene family, member A (RhoA), Jun N-
terminal kinase (JNK), mitogen-activated protein kinase (MAPK)
and nuclear factor kappa B (NFjB) [2]. These pathways are shown
to be activated by upstream proteins that directly associate with
various regions of the p75NTR intracellular domain. For example,
guanine nucleotide dissociation inhibitor, ribosome-inactivating
protein-2 (RIP-2), is able to associate with the death domain of
p75NTR; tumor necrosis factor (TNF) receptor-associated factor
(TRAF), can associate with the juxtamembrane region of p75NTR;
PDZ-containing protein Fas-associated phosphatease-1 (FAP-1)
can associate with the C-terminal Ser-Pro-Val [10]. In addition to
associating with signaling molecules, p75NTR, like an increasing
number of proteins including b-amyloid precursor protein (APP)
and Notch, undergoes regulated two-step proteolysis. Full-length
p75NTR is initially cleaved in its extracellular juxtamembrane
domain, leading to the release of the neurotrophin-binding
extracellular domain and the production of a membrane-bound
carboxyl-terminal fragment (CTF) [11]. The enzyme responsible
for this cleavage is the tumor necrosis factor-a-converting enzyme
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the ﬁrst cleavage, the transmembrane domain is then cleaved by
presenilin-dependent c-secretase activity, yielding a soluble intra-
cellular fragment (ICD) [11]. These cleavages may regulate the abil-
ities of the membrane bound C-terminal fragment and the
intracellular domain to interact with downstream partners,
explaining the diversity of functions mediated by p75NTR [13].
In this work, we ﬁrst determined if p75NTR underwent regulated
proteolysis in breast cancer cells and then evaluated the impact of
p75NTR proteolysis in p75NTR-mediated cellular survival. Our re-
sults indicate that p75NTR proteolysis does occur in breast cancer
cells. Moreover, the product of ﬁrst cleavage (CTF) is involved in
p75NTR-mediated survival while the product of second cleavage
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Fig. 1. Western blot detection of p75NTR proteolytic processing in MDA-MB-231
breast cancer cells. (A) Cells were treated with different concentrations of
pronasterone A (PA) during 24 h for the detection of p75NTR-FL and p75NTR-CTF.
(B) Effect of MG132 (proteasome inhibitor), compound E (c-secretase inhibitor) and
TAPI-1 (MMPs/ADAMs inhibitor) on p75NTR processing. Cells were treated with
10 lM PA for 24 h and then treated for 1 h with 5 lMMG132, 1 lM compound E, or
10 lM TAPI-1. Actin was used as a loading control.2. Materials and methods
2.1. Reagents
Tumor necrosis factor-a protease inhibitor 1 (TAPI-1), com-
pound E, LY294002, PD98059, BAY117082 and MG132 were pur-
chased from Calbiochem. TNF-related apoptosis-inducing ligand
(TRAIL) and hepatocyte growth factor (HGF) were purchased from
R&D system.
2.2. Cell culture and transfection
MDA-MB-231 and BT-20 breast cancer cell lines were obtained
from the American Type Culture Collection. Cells were routinely
maintained in monolayer cultures in minimal essential medium
(MEM) (Gibco) supplemented with 10% fetal bovine serum (FBS;
Perbio). The inducible p75NTR overexpressing MDA-MB-231 cells
were established as described previously [8], and p75NTR overex-
pression was induced by treating cells with ponasterone A (PA;
Sigma Aldricht) 10 lM for 24 h. To test the effect of p75NTR cleav-
ages, breast cancer cells were transfected by nucleofection
(Amaxa) with siRNA against ADAM17 50-GGAAGCUGACCUGGUU-
ACAACUCAU-30, or presenilin 1 (PS1) 50-AAGGUCCACUUCGUAUG-
CUGGTT-30, or control siRNA 50-GCUGACCCUGAAGUUCAUC-30
according to manufacturer’s instructions. Cells were then cultured
for 24 h before PA induction. For transient expression experiments,
MDA-MB-231 cells (3  105 cells/well) were seeded in six-well
dishes. Transfections were performed using Lipofectamine™ 2000
Transfection Reagent (Invitrogen) according to manufacturer’s
instructions. For luciferase activity assay, 100 ng of jB luciferase
reporter construct and 25 ng of normalizing vector pRLnull was
cotransfected with 1 lg of DNA of interest. Cells were incubated
with the reagents for 5 h at 37 C before the culture medium was
replaced with fresh one for further culture. To measure the repor-
ter activity, cells were harvested 24 h after transfection using a
passive lysis buffer (Promega) and lysates were clariﬁed by centri-
fugation. Luciferase assay was performed using a Luciferase assay
system (Promega) and Luciferase activities were measured using
a lumat LB 9501 (Berthold). Triplicate samples were performed
in each experiment, and standard deviations (S.D.) are shown.
2.3. Plasmids
Vectors containing full length p75NTR (p75NTR wt), a chimeric
receptor in which the transmembrane domain of the FasR was
introduced into p75NTR (P3) were generous gifts of Dr. Moses V.
Chao [11]. The p75NTR-ICD encoding vector was a generous gift of
Dr. Philip A Barker [14]. p75NTR-CTF was performed as following:
CTF fragment was fused to GFP (green ﬂuorescent protein) in pEG-
FP C1 vector (Promega) and GFP-CTF was cloned in phase withtransmembrane domain of p75NTR in PCDNA3 vector. The normal-
izing vector pRLnull has no promoter sequence to drive expression
of the Renilla luciferase gene and was purchased from Promega.
The jB luciferase reporter construct has ﬁve NF-jB-responsive ele-
ments in tandem and was purchased from Stratagene.
2.4. Western blot
Cells were lysed in lysis buffer (20 mM Tris–HCl pH 7.4, 50 mM
NaCl, 5 mM EDTA, 1% Triton X-100) and western blot was per-
formed as previously described [8]. Anti-actin (sc-47778), anti-
ERK2 (sc-154), anti-PARP (sc-7150) antibodies were purchased
from Santa Cruz Biotechnology. Anti-PS1 (#3622), anti-TACE/
ADAM17 (#3976), anti-cleaved caspase 3 (#9664), anti-AKT
(#2920), anti-phosphoAKT (#4060), anti-phophoERK (#91065)
antibodies were purchased from Cell Signalling Technology. Anti-
p75NTR (G323A) antibody was purchased from Promega.
2.5. Measurement of cell survival or cell death
(i) Hoechst staining. After treatment by TRAIL (4 ng/ml for 4 h)
or transfection, cells were ﬁxed with ice-cold methanol (20 C)
for 10 min and washed twice with phosphate-buffered saline
(PBS) before incubation with 1 mg/ml Hoechst 33258 for 10 min
at room temperature in the dark. Cells were then washed with
PBS and mounted with coverslips using Glycergel (Dako). The
apoptotic cells exhibiting condensed and fragmented nuclei were
counted under an Olympus-BH2 ﬂuorescence microscope in ran-
domly selected ﬁelds. (ii) Flow cytometry analysis. 48 h after trans-
fection of p75NTR derived-vectors, cells were treated with TRAIL,
washed and stained with 50 lg/ml propidium iodide (PI) (Sigma)
according to the manufacturer’s instructions. Cell death was
S. Verbeke et al. / FEBS Letters 587 (2013) 2591–2596 2593measured by ﬂow cytometry analysis (CyAn™ ADP Analyzer-Beck-
man Coulter) of PI positive cells.
2.6. Statistical analysis
Statistical analysis was performed using unpaired Student’s t-
test. A value of P < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. p75NTR is sequentially cleaved in breast cancer cells
The regulated intramembrane proteolysis (RIP) of p75 receptor
has been widely described in neurons. It involves two sequential
cleavages of full length p75NTR, generating a membrane-bound C-
terminal fragment (CTF) and a soluble intracellular fragment ICD
[13]. We previously established a p75NTR overexpressing breast
cancer cell model in which p75NTR functions to promote cell sur-
vival [8]. We therefore wanted to determine whether intramem-
brane proteolysis of p75NTR could occur in these cells. We
performed Western blot using a p75NTR cytoplasmic-speciﬁc anti-
body. As shown in Fig. 1A, treatment of cells with PA induced the
expression of full length p75NTR protein (p75NTR-FL) in a dose
dependent manner. Moreover, the levels of 25 kDa CTF fragment






















































































Fig. 2. Effect of cleavage inhibitors on p75NTR antiapoptotic activity. (A) MDA-MB-231 cel
before induction of apoptosis with TRAIL (4 ng/ml, 4 h). Apoptosis was detected as descri
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siRNAs against ADAM17 or presenilin 1 (PS1) and then treated with PA as described in m
determined using the student t-test (⁄P < 0.05). Efﬁciency of siRNAs was veriﬁed by Weintracellular domain, which ordinarily undergoes rapid protea-
some degradation, we treated cells with a proteasome inhibitor
(MG132) as previously described [15]. As shown in Fig. 1B a
20 kDa fragment corresponding to the p75NTR-ICD was detected
upon MG132 treatment. Next, we veriﬁed that these fragments
were the results of sequential cleavages by using an inhibitor of
metalloproteases and a disintegrin and metalloproteases (ADAMs)
(TAPI-1) and a c-secretase inhibitor (compound E). Western blot
analysis revealed that treatment of cells with compound E led to
the disappearance of the 20 kDa fragment (p75NTR-ICD) with a con-
comitant accumulation of the 25 kDa fragment (p75NTR-CTF),
whereas TAPI-1 (impairing the ﬁrst cleavage) treatment resulted
to the lack of both p75NTR-CTF and p75NTR-ICD (Fig. 1B). These re-
sults demonstrate that extracellular cleavage of p75NTR in MDA-
MB-231 breast cancer cells precedes intracellular cleavage as it
has been previously shown in neurons [13].
3.2. Extracellular cleavage is involved in p75NTR-induced survival of
breast cancer cells
Proteolytic processing of p75NTR generates an ICD fragment,
which is involved in the activation of downstream events and
the biological functions of p75NTR [13]. To test whether the pro-
cessing of p75NTR has a functional role in breast cancer cell sur-
vival, we pre-treated MDA-MB-231 cells with PA to induce- - + + A-p75NTR
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Fig. 3. Effects of p75NTR fragments on TRAIL-induced cell death. (A and B) MDA-MB-231 cells were transfected with control vector, ICD, P3, p75NTR wt or p75NTR-CTF encoding
vectors. Twenty-four hours after transfection, cells were treated with 4 ng/ml TRAIL for 4 h. PARP and caspase 3 cleavages were analyzed by Western blot. Actin was used as
loading control. (C) MDA-MB-231 cells were treated with PA for 24 h and then treated with compound E for 1 h before induction of apoptosis with TRAIL (4 ng/ml, 4 h).
Western blot analysis was performed to detect the cleavage of PARP and caspase 3. (D) MDA-MB-231 cells were transfected with different forms of p75NTR. Twenty-four hours
after transfection, cells were treated with 4 ng/ml TRAIL for 4 h before analysis of cell death (PI-positive cells) by ﬂow cytometry. Experiments were performed in triplicate
and results are expressed as the means ± S.D. of two separate experiments. Signiﬁcance was determined using the student t test (⁄P < 0.05; ⁄⁄P < 0.01). (E) Western blot
analysis of PARP cleavage in BT-20 breast cancer cells. Cells were transfected with indicated vectors and then treated with TRAIL before Western blot analysis. (F) Evaluation
of cell death in BT-20 cells. Experiments were performed as described in Fig. 3D.
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with TRAIL, with or without inhibition of PA-p75NTR cleavage.
Apoptosis induction by TRAIL is measured after Hoechst staining.
As shown in Fig. 2A, inhibition of c-secretase by compound E
had no effect on the pro-survival effect of PA-p75NTR whereas
TAPI-1 abolished this effect. To further conﬁrm these results, we
attempted to specially inhibit ADAM17 or presenilin 1 (PS1), a
member of c-secretase multiprotein complex, by using siRNAs.
As shown in Fig. 2B, knock-down of ADAM17 by speciﬁc siRNA
decreased p75NTR-CTF and abolished the anti-apoptotic effect of
PA-p75NTR in MDA-MB-231 cells. On the other hand, knock-down
of PS1 increased p75NTR-CTF and preserved PA-p75NTR-mediated
cell survival (Fig. 2C). The efﬁcacy of siRNAs was veriﬁed by Wes-
tern blot (Fig. 2B and C). These results showed that inhibition of the
ﬁrst cleavage abolished the pro-survival effect of PA-p75NTR
whereas inhibition of the second cleavage had no effect.3.3. p75NTR-CTF is able to protect breast cancer cells against TRAIL-
induced cell death
To further prove that p75NTR proteolysis is involved in breast
cancer cell survival, we transfected MDA-MB-231 cells with
p75NTR wt encoding vector, a p75NTR chimeric construct containing
Fas transmembrane region (P3), a p75NTR-ICD or p75NTR-CTF
encoding vector. After transfection, cell lysates were analyzed by
Western blot. A reduction of PARP and caspase 3 cleavages was ob-
served in cells transfected with p75NTR, P3, or p75NTR-CTF (Fig. 3A
and B), suggesting that these cells were more resistant to TRAIL-in-
duced apoptosis. Similarly, when PA-induced p75NTR overexpress-
ing cells are treated with compound E to avoid CTF cleavage into
ICD fragment, a reduction of PARP and caspase 3 cleavages was
also observed (Fig. 3C). In contrast, ICD expression did not modify
the cleavage of either PARP or caspase 3 (Fig. 3 A). We then quan-
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Fig. 4. Implication of PI3-kinase, MAP kinase and NF-jB pathways on the pro-survival effect of p75NTR. (A) MDA-MB-231 cells were treated PA for 24 h to induce p75NTR
expression. Cells treated with HGF were used as positive controls. The efﬁciency of inhibitors of PI3-kinase (LY294002), MAP kinase (PD98059) and NF-jB (BAY117082) was
assessed by Western blot or luciferase activity as described in Section 2. Luciferase activity was measured and reported to cells cultured in the absence of BAY117082.
Experiments were performed in triplicate and results are expressed as the means ± S.D. (B) MDA-MB-231 cells were treated with TRAIL in the presence or absence of
pharmacological inhibitors. Experiments were performed in triplicate and results are expressed as the means ± S.D. of three separate experiments. Signiﬁcance was
determined using the student t test (⁄P < 0.05; ⁄⁄P < 0.01).
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propidium iodide (Fig. 3D). We found that p75NTR WT, P3 (unable
to generate ICD) and p75NTR-CTF decreased cell death whereas
ICD had no effect. When another BT-20 breast cancer cell line
was analyzed after transfection with different p75NTR encoding
vectors, similar results were obtained in terms of both PARP cleav-
age (Fig. 3E) and cell survival (Fig. 3F) upon TRAIL treatment. To-
gether, these ﬁndings indicated that p75NTR-CTF alone could
exert the pro-survival effect in breast cancer cells.
3.4. Pro-survival effect of p75NTR is independent of PI3-kinase, MAP
kinase and NF-B pathways
p75NTR has been described to exert its diverse biological effects
by activating several pathways including PI3-kinase, MAP kinase
and NF-jB pathways [2]. To precise the mechanism of action of
p75NTR in our model, we pre-treated MDA-MB-231 cells with PA
to induce p75NTR overexpression (PA-p75NTR) before addition of
pharmacological inhibitors of PI3-kinase (LY294002), MAP kinase
(PD98059), or NF-jB (BAY117082). HGF (hepatocyte growth fac-
tor), well described for the activation of the above signaling path-
ways and pro-survival effect [16], was used as a positive control. As
shown in Fig. 4A, PA-p75NTR overexpression per se slightly in-
creased the phosphorylation of Akt and Erk, but increased NF-jB
activity in a similar degree to the positive control (HGF). Treatment
of cells with pharmacological inhibitors of PI3-kinase, MAP kinase
or NF-jB pathways efﬁciently abolished both PA-p75NTR overex-
pression- and HGF-induced phosphorylation of Akt and Erk, as well
as NF-jB activation. p75NTR-CTF was detected whatever the pres-
ence of pharmacological inhibitors. We then tested the anti-apop-totic effect of PA-p75NTR by treating MDA-MB-231 cells with TRAIL
in the presence of speciﬁc signaling pathway inhibitors (Fig. 4B).
Both PA-p75NTR overexpression and HGF treatment were able to
diminish TRAIL-induced apoptosis. Interestingly, inhibition of
PI3-kinase, MAP kinase and NF-jB pathways abolished the pro-
survival effect of HGF but did not modify the pro-survival effect
of PA-p75NTR. Moreover, in cells transfected with different p75NTR
encoding vectors, no modiﬁcation of pAkt or pErk was detected
whatever the expressed forms of p75NTR (data not shown). These
results, together with the above results shown in Fig. 3, indicate
that the pro-survival effect of p75NTR was due to p75NTR-CTF, which
could act in a manner independent of PI3-kinase, MAP kinase and
NF-jB pathways.
4. Discussion
The role of p75NTR in tumorigenesis is still controversial. It has
been proposed as a potential tumor suppressor in carcinomas of
prostate, bladder, stomach and liver. In these cancers, p75NTR is
downregulated and ectopic re-expression of p75NTR inhibits cell
proliferation [17] and induces apoptosis [18]. In other cancers
including melanoma, pancreatic carcinoma, glioma and breast can-
cer, p75NTR exerts rather a tumor-promoting function by favoring
survival and invasion of cancer cells [9,19,20]. We have previously
demonstrated that neurotrophins (NGF, BDNF and NT-4/5) and
their common receptor p75NTR are overexpressed in breast cancers
[7,9,21]. Ectopic overexpression of p75NTR increases cell survival
in vitro and tumor growth in xenograft mouse model [8], while
inhibition of p75NTR decreases cell survival in vitro and tumor
growth in xenograft mouse model [9].
2596 S. Verbeke et al. / FEBS Letters 587 (2013) 2591–2596To further investigate the role of p75NTR in breast cancer cell
growth, we established a model of inducible expression of p75NTR
using MDA-MB-231 breast cancer cells [8]. We demonstrated here
that p75NTR underwent regulated two-step proteolysis in breast
cancer cells as described in other types of cells. Moreover, we
found that the product of the ﬁrst cleavage (CTF) was involved in
p75NTR-mediated survival while the product of the second cleavage
(ICD) had no effect. Our ﬁndings are consistent with the increasing
data reporting the importance of regulated proteolysis of p75NTR in
the diverse functions of p75NTR [13]. In general, the CTF fragment is
considered as an intermediary product which is converted to the
soluble ICD fragment, able to activate different signaling pathways
to promote survival, cell death or even cell invasion. For example, it
has been shown that the p75NTRICD increases basal Akt phosphor-
ylation in PC12nnr cells if highly overexpressed [22]. More re-
cently, it has been described that in PC12 cells and in primary
cerebellar granule neurons, NGF activation of TrkA leads to
ADAM17 phosphorylation and generation of the p75NTRICD, which
in turn activates Erk and Akt survival signaling [23].
However, it has been also reported that the membrane-associ-
ated CTF can promote cell death in neurons when over-expressed
in a form that cannot be cleaved to generate the ICD [24]. In these
cases, CTF is found to be translocated to cholesterol-rich domains
of the plasma membrane, where CTF exerts its death-inducing ef-
fect due to the presence of the cytoplasmic juxtamembrane region
known as the ‘Chopper domain’. The second cleavage by c-secre-
tase avoids cell death in these conditions [25].
p75NTR exerts its diverse effects through several signaling path-
ways include Ras homolog gene family, member A (RhoA), Jun N-
terminal kinase (JNK), mitogen-activated protein kinase (MAPK),
NF-jB [2]. However, in our model, inhibition of well-known sur-
vival pathways such as PI3-kinase, NF-jB, MAP kinase did not im-
pair the pro-survival effect of p75NTR.
Although more basic studies are clearly needed to understand
the mechanism of action of p75NTR, our results emphasized the
crucial role of p75NTR processing in its pro-survival function. To
our knowledge, this is the ﬁrst report describing a survival role
of p75NTR-CTF. The ADAM metalloproteinase disintegrins, includ-
ing ADAM17 and ADAM10, have been described as prominent
sheddases for p75NTR as well as other transmembrane type-1
receptors. In this study, we observed that ADAM17 inhibition by
siRNA approach or pharmacological inhibitor abolished the pro-
survival effect of p75NTR in MDA-MB-231 triple negative breast
cancer cells. Interestingly, ADAM17 is found to be overexpressed
in triple-negative breast cancer [26]. We can hypothesize that
co-expression of both ADAM17 and p75NTR would favor the
generation of p75NTR-CTF and enhance tumor resistance to drugs.
Our results provide thus a rationale to consider p75NTR as a poten-
tial target for the future design of innovative therapeutic strategies.
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